Asthma and COPD Inhalers Pocket Card 2026 (GINA and GOLD)

An updated pocket card on asthma and COPD inhalers for pharmacy and medical students: inhaler classes, GINA 2026 asthma steps, GOLD COPD treatment, acute attacks, inhaler technique and side effects.

Asthma & COPD Inhalers Pocket Card 2026
Inhaled medicines and treatment steps · based on GINA 2026 and GOLD 2026/2027
Preferred preferred option   Alt alternative   Avoid avoid  |  ICS = inhaled corticosteroid · SABA/LABA = short/long-acting beta-agonist · LAMA = long-acting antimuscarinic · MART = maintenance and reliever therapy
Inhaler classes
  • SABA (reliever): salbutamol 100-200 mcg as needed; terbutaline
  • ICS: beclometasone, budesonide, fluticasone, ciclesonide; rinse mouth after use
  • ICS-formoterol: budesonide-formoterol 200/6, beclometasone-formoterol 100/6: works as reliever and controller
  • LABA: salmeterol, formoterol, indacaterol, olodaterol, vilanterol; never alone in asthma
  • LAMA: tiotropium, umeclidinium, glycopyrronium, aclidinium
  • Combinations: ICS-LABA, LABA-LAMA, triple ICS-LABA-LAMA single inhaler
Asthma (adults, GINA 2026 Track 1)
  • Preferred Steps 1-2: as-needed low-dose ICS-formoterol (anti-inflammatory reliever); no daily inhaler needed
  • Preferred Step 3: low-dose ICS-formoterol MART (daily + as needed)
  • Preferred Step 4: medium-dose ICS-formoterol MART
  • Preferred Step 5: add LAMA; refer for phenotyping; biologics (anti-IgE, anti-IL5, anti-IL4R, anti-TSLP)
  • Alt Track 2: SABA reliever with ICS each time, or regular ICS / ICS-LABA; ICS-SABA reliever now an option
  • Avoid SABA alone: never treat asthma with a SABA only (higher risk of severe attacks and death)
COPD (GOLD)
  • Group A: one long-acting bronchodilator; GOLD 2027 prefers a LAMA
  • Group B (more symptoms): Preferred LABA + LAMA, ideally one inhaler
  • Group E (1 or more exacerbations): LABA + LAMA; consider triple therapy if blood eosinophils 300/µL or more
  • Exacerbations on LABA+LAMA: add ICS (triple) if eosinophils 100/µL or more; roflumilast or azithromycin in selected patients
  • Biologics: dupilumab or mepolizumab for exacerbation-prone eosinophilic COPD
  • Avoid ICS-LABA without LAMA: in COPD; if ICS is needed, use triple therapy
Acute attacks
  • Asthma attack: SABA 4-10 puffs by spacer every 20 min for 1 h, or ICS-formoterol extra doses (max 72 mcg formoterol/day); oxygen to SpO2 93-95%
  • Oral steroid: prednisolone 40-50 mg daily for 5-7 days (children 1-2 mg/kg, max 40 mg)
  • Severe asthma: ipratropium nebs, IV magnesium sulfate 2 g, ICU if not improving
  • COPD exacerbation: SABA ± ipratropium, prednisolone 40 mg for 5 days, antibiotics if sputum purulent; oxygen target 88-92%
  • Danger signs: cannot speak sentences, SpO2 under 92% (asthma), silent chest, confusion, rising CO2
Inhaler technique
  • pMDI: shake, breathe out, seal lips, press and breathe in slowly and deeply, hold 10 s; use a spacer if coordination is poor
  • Dry powder inhaler (DPI): do not shake; breathe in fast and deep; never breathe into the device
  • Soft mist (Respimat): slow deep breath while pressing
  • Check: technique at every visit: most "treatment failure" is wrong technique or poor adherence
  • After ICS: rinse mouth and spit to prevent oral thrush and hoarse voice
Side effects & safety
  • SABA/LABA: tremor, fast heartbeat, low potassium (high doses)
  • LAMA: dry mouth, urinary retention, caution in narrow-angle glaucoma
  • ICS: oral thrush, hoarseness; in COPD higher pneumonia risk
  • Beta-blockers: non-selective ones can trigger asthma attacks; cardioselective are usually safe in COPD
  • NSAIDs / aspirin: can trigger attacks in aspirin-sensitive asthma
  • Every COPD patient: stop smoking, vaccines (flu, pneumococcal, COVID-19, RSV), pulmonary rehabilitation
Adult doses and steps; children have separate GINA steps. Always follow local guidelines and the prescriber. Sources: GINA 2026 Strategy Report; GOLD 2026 and 2027 Reports.

Details behind the card

1. What is new?

  • GINA 2026: as-needed ICS-formoterol remains the preferred reliever for adults and adolescents; ICS-SABA has been added as a Step 1 option in Track 2, and dosing for AIR and MART has been simplified.
  • No SABA-only treatment for asthma at any age, including children.
  • GOLD 2026: even one moderate exacerbation now places a patient in group E; blood eosinophils guide ICS use; dupilumab and mepolizumab are recognised add-on biologics.
  • GOLD 2027: a LAMA is now the preferred initial treatment for group A, and CT is recommended at least once where available.

2. Asthma vs COPD

FeatureAsthmaCOPD
Age of onsetOften childhood or young adultUsually over 40, smoker or biomass exposure
SymptomsVariable, worse at night, triggersPersistent, slowly progressive breathlessness
Airflow limitationReversibleNot fully reversible (FEV1/FVC under 0.7 after bronchodilator)
Main controllerICS (with formoterol)LAMA / LABA bronchodilators
ICS roleEssential in all patientsOnly if eosinophils high or frequent exacerbations

3. Counselling checklist

  • Show and check inhaler technique; a spacer makes pMDIs work much better.
  • Explain reliever vs preventer; with MART one inhaler does both.
  • Carry the reliever at all times; seek help if needing it much more than usual.
  • Know your triggers: dust, smoke, cold air, pollen, infections; avoid smoking and biomass smoke (chulha).
  • Have a written asthma action plan.

4. Special groups

  • Children 6-11: low-dose ICS-formoterol MART is an option from Step 3; under 5 years use pMDI with spacer and mask.
  • Pregnancy: continue asthma medicines; uncontrolled asthma is more dangerous to the baby than ICS.
  • Elderly: choose a device they can use; soft-mist or pMDI with spacer if inspiratory flow is weak.

Remember for exams

  • Asthma: never SABA alone; preferred reliever is ICS-formoterol.
  • MART = maintenance and reliever therapy with ICS-formoterol (from Step 3).
  • COPD: LABA + LAMA for groups B and E; triple if eosinophils 300/µL or more.
  • Avoid ICS-LABA without LAMA in COPD.
  • Oxygen target: asthma 93-95%, COPD 88-92%.
  • Rinse mouth after ICS to prevent thrush.

Sources

  • Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention, 2026.
  • Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2026 and 2027 Reports.
  • Product information (SmPC) for individual inhalers.

Important: this card is for education and revision. Treatment decisions must follow local guidelines and the treating doctor. More pocket cards: Clinical Pocket Cards

No comments:

Post a Comment